Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis

Exclusion Criteria

• •1. Women who are pregnant or nursing.
• •2. History of any other types of lung or heart disease and any other medical conditions that, in the opinion of the investigator, would preclude the subject's participation in the study.
• •3. Clinically important abnormal laboratory tests.
• •4. Upper or lower respiratory tract infection of any type within 4 weeks of the first screening visit.
• •5. Acute exacerbation of IPF within 3 months of the first screening visit.
• •6. Use of certain medications within 4 weeks of the first screening visit.
• •7. Receipt of an investigational drug within 6 weeks of the first screening visit.
• •8. History of cancer of any type in the 5 years preceding the first screening visit, excluding non-melanomatous skin cancer, localized bladder cancer, or in situ cervical cancer.
• •9. Trauma or surgical procedures requiring hospitalization within 4 weeks of the first screening visit.
• •10. Planned elective surgery during the study including 4 weeks following the final dose of study drug.
• •11. History of allergic or anaphylactic reaction to human, humanized, chimeric or murine monoclonal antibodies.
• •12. Inability to cooperate with study personnel or history of non-compliance to a medical regimen.
• •13. Previous treatment with FG-3019.